Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 5/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 11/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14749325 | 0.89 | PRCP (0.49) | PRCPHSD11B1RAB9ACNR1GPR55 | |
| SCHEMBL14736875 | 0.86 | PRCP (0.59) | PRCPMEN1KMT2A | |
| SCHEMBL14749359 | 0.83 | PRCP (0.55) | PRCPHSD11B1 | |
| SCHEMBL14749343 | 0.80 | PRCP (0.56) | PRCP | |
| SCHEMBL14749336 | 0.80 | PRCP (0.55) | PRCPSMN1; SMN2 | |
| SCHEMBL14749364 | 0.80 | PRCP (0.55) | PRCPSMN1; SMN2 | |
| SCHEMBL14749417 | 0.80 | PRCP (0.51) | PRCPMEN1KMT2ASMN1; SMN2CNR1 | |
| SCHEMBL14749360 | 0.80 | PRCP (0.60) | PRCP | |
| SCHEMBL14749328 | 0.79 | PRCP (0.61) | PRCPSMN1; SMN2 | |
| SCHEMBL14749327 | 0.78 | PRCP (0.50) | PRCP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130059830-A1 | NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS | MERCK SHARP & DOHME CORP | 2013-03-07 | — | — | US | disclosed |
| US-20130059830-A1 | NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS | MERCK SHARP & DOHME CORP | 2013-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130059830-A1 | NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS | PRCP, PREP, ENPEP | PRCP 1/4885MEN1 3238/4885KMT2A 2172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.